Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence

International Journal of Obesity

Volumn 40, Issue 4, 2016, Pages 622-632

  Lean, M E J ^a,b   Malkova, D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CORTICOSTEROID; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; PANCREAS HORMONE; PANCREAS POLYPEPTIDE; PEPTIDE YY;

ADIPOSE TISSUE; BARIATRIC SURGERY; BODY COMPOSITION; BODY WEIGHT; COMPARATIVE STUDY; DIET; EXERCISE; FOOD INTAKE; HORMONE RESPONSE; HUMAN; INCREASED APPETITE; INTESTINAL TISSUE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WEIGHT REDUCTION; APPETITE; CALORIC INTAKE; ENERGY METABOLISM; GASTROINTESTINAL TRACT; METABOLISM; OVERWEIGHT; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTPRANDIAL STATE; REFERENCE VALUE; SATIETY;

ADIPOSE TISSUE; APPETITE; APPETITE REGULATION; ENERGY INTAKE; ENERGY METABOLISM; GASTROINTESTINAL HORMONES; GASTROINTESTINAL TRACT; HUMANS; OBESITY; OVERWEIGHT; POSTPRANDIAL PERIOD; REFERENCE VALUES; SATIATION; WEIGHT LOSS;

EID: 84949035550     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.220     Document Type: Review

References (148)

1. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-825.
2. Atkinson RL. Current status of the field of obesity. Trends Endocrinol Metab 2014; 25: 283-284.
3. Vlassopoulos A, Combet E, Lean ME. Changing distributions of body size and adiposity with age. Int J Obes 2013; 38: 857-864.
4. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1-7.
5. Gibson CD, Carnell S, Ochner CN, Geliebter A. Neuroimaging, gut peptides and obesity: novel studies of the neurobiology of appetite. J Neuroendocrinol 2010; 22: 833-845.
6. Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Annu Rev Physiol 2008; 70: 239-255.
7. Stimac D, Klobucar Majanovic S, Franjic N. Stomach-key player in the regulation of metabolism. Dig Dis 2014; 32: 192-201.
8. Folgueira C, Seoane LM, Casanueva FF. The brain-stomach connection. Front Horm Res 2014; 42: 83-92.
9. Grimm ER, Steinle NI. Genetics of eating behavior: established and emerging concepts. Nutr Rev 2011; 69: 52-60.
10. Redman LM, Kraus WE, Bhapkar M, Das SK, Racette SB, Martin CK, et al. Energy requirements in nonobese men and women: results from CALERIE. Am J Clin Nutr 2014; 99: 71-78.
11. Garrow JS. Obesity. Encyclopedia of Life Sciences. John Wiley & Sons Malden, MA, USA, 2001.
12. Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5: 621-626.
13. Colon-Gonzalez F, Kim GW, Lin JE, Valentino MA, Waldman SA. Obesity pharmacotherapy: what is next? Mol Aspects Med 2013; 34: 71-83.
14. Lowe MR, Butryn ML. Hedonic hunger: a new dimension of appetite? Physiol Behav 2007; 91: 432-439.
15. Delzenne N, Blundell J, Brouns F, Cunningham K, De Graaf K, Erkner A, et al. Gastrointestinal targets of appetite regulation in humans. Obes Rev 2010; 11: 234-250.
16. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13-23.
17. Field BC. Neuroendocrinology of obesity. Br Med Bull 2014; 109: 73-82.
18. Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 2004; 55: 137-154.
19. Schwartz GJ. Integrative capacity of the caudal brainstem in the control of food intake. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1275-1280.
20. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1187-1209.
21. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010; 57: 359-372.
22. Yu JH, Kim MS. Molecular mechanisms of appetite regulation. Diabetes Metab J 2012; 36: 391-398.
23. Blundell JE, Finlayson G. Is susceptibility to weight gain characterized by homeostatic or hedonic risk factors for overconsumption? Physiol Behav 2004; 82: 21-25.
24. Berridge KC. Liking and wanting food rewards: brain substrates and roles in eating disorders. Physiol Behav 2009; 97: 537-550.
25. Critchley HD, Rolls ET. Hunger and satiety modify the responses of olfactory and visual neurons in the primate orbitofrontal cortex. J Neurophysiol 1996; 75: 1673-1686.
26. Muller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab 2015; 4: 437-460.
27. Rolls ET. Taste, olfactory and food texture reward processing in the brain and obesity. Int J Obes 2011; 35: 550-561.
28. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond) 2015; 39: 1188-1196.
29. Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012; 122: 153-162.
30. Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. The role of mixed orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa. Int J Endocrinol 2013; 2013: 483145.
31. Beglinger C, Degen L. Gastrointestinal satiety signals in humans-physiologic roles for GLP-1 and PYY? Physiol Behav 2006; 89: 460-464.
32. Dockray GJ. Gastrointestinal hormones and the dialogue between gut and brain. J Physiol 2014; 592: 2927-2941.
33. Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011; 8: 418-431.
34. Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 2014; 16: 9-21.
35. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulindependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
36. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-Dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
37. Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rossner S, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-Diabetic adults. Int J Obes (Lond) 2014; 38: 689-697.
38. Adam TC, Westerterp-Plantenga MS. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br J Nutr 2005; 93: 845-851.
39. Carroll JF, Kaiser KA, Franks SF, Deere C, Caffrey JL. Influence of BMI and gender on postprandial hormone responses. Obesity 2007; 15: 2974-2983.
40. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-Effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001; 25: 1206-1214.
41. Bowen J, Noakes M, Clifton PM. Appetite regulatory hormone responses to various dietary proteins differ by body mass index status despite similar reductions in ad libitum energy intake. J Clin Endocrinol Metab 2006; 91: 2913-2919.
42. Sloth B, Due A, Larsen TM, Holst JJ, Heding A, Astrup A. The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. Br J Nutr 2009; 101: 1846-1858.
43. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-Term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-1604.
44. Martins C, Kulseng B, King NA, Holst JJ, Blundell JE. The effects of exerciseinduced weight loss on appetite-related peptides and motivation to eat. J Clin Endocrinol Metab 2010; 95: 1609-1616.
45. Schubert MM, Sabapathy S, Leveritt M, Desbrow B. Acute exercise and hormones related to appetite regulation: a meta-Analysis. Sports Med 2014; 44: 387-403.
46. Pironi L, Stanghellini V, Miglioli M, Corinaldesi R, De Giorgio R, Ruggeri E, et al. Fat-induced ileal brake in humans: a dose-Dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology 1993; 105: 733-739.
47. De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 2012; 6: 10-20.
48. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-1077.
49. le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147: 3-8.
50. Yang N, Liu X, Ding EL, Xu M, Wu S, Liu L, et al. Impaired ghrelin response after high-fat meals is associated with decreased satiety in obese and lean Chinese young adults. J Nutr 2009; 139: 1286-1291.
51. Feinle-Bisset C, Patterson M, Ghatei MA, Bloom SR, Horowitz M. Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 2005; 289: E948-E953.
52. Essah PA, Levy JR, Sistrun SN, Kelly SM, Nestler JE. Effect of macronutrient composition on postprandial peptide YY levels. J Clin Endocrinol Metab 2007; 92: 4052-4055.
53. Brownley KA, Heymen S, Hinderliter AL, MacIntosh B. Effect of glycemic load on peptide-YY levels in a biracial sample of obese and normal weight women. Obesity 2010; 18: 1297-1303.
54. Cahill F, Shea JL, Randell E, Vasdev S, Sun G. Serum peptide YY in response to short-Term overfeeding in young men. Am J Clin Nutr 2011; 93: 741-747.
55. Zwirska-Korczala K, Konturek SJ, Sodowski M, Wylezol M, Kuka D, Sowa P, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 2007; 58: 13-35.
56. Jones TE, Basilio JL, Brophy PM, McCammon MR, Hickner RC. Long-Term exercise training in overweight adolescents improves plasma peptide YY and resistin. Obesity (Silver Spring) 2009; 17: 1189-1195.
57. Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley MA, Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 2005; 90: 6386-6391.
58. Guelfi KJ, Donges CE, Duffield R. Beneficial effects of 12 weeks of aerobic compared with resistance exercise training on perceived appetite in previously sedentary overweight and obese men. Metabolism 2013; 62: 235-243.
59. Jayasena CN, Bloom SR. Role of gut hormones in obesity. Endocrinol Metab Clin North Am 2008; 37: 769-787; xi.
60. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-3992.
61. Adamska E, Ostrowska L, Gorska M, Kretowski A. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. Prz Gastroenterol 2014; 9: 69-76.
62. Reinehr T, Enriori PJ, Harz K, Cowley MA, Roth CL. Pancreatic polypeptide in obese children before and after weight loss. Int J Obes (Lond) 2006; 30: 1476-1481.
63. Jensen DE, Nguo K, Baxter KA, Cardinal JW, King NA, Ware RS, et al. Fasting gut hormone levels change with modest weight loss in obese adolescents. Pediatr Obes 2015; 10: 380-387.
64. Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, et al. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans: studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 1991; 101: 503-511.
65. Matzinger D, Gutzwiller JP, Drewe J, Orban A, Engel R, D'Amato M, et al. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. Am J Physiol 1999; 277: R1718-R1724.
66. Konturek P, Konturek S. The history of gastrointestinal hormones. J Physiol Pharmacol 2003; 54: 83-98.
67. Huda M, Wilding J, Pinkney J. Gut peptides and the regulation of appetite. Obes Rev 2006; 7: 163-182.
68. Wren A, Bloom S. Gut hormones and appetite control. Gastroenterology 2007; 132: 2116.
69. Delzenne N, Blundell J, Brouns F, Cunningham K, De Graaf K, Erkner A, et al. Gastrointestinal targets of appetite regulation in humans. Obes Rev 2010; 11: 234-250.
70. Zac-Varghese S, Tan T, Bloom SR. Hormonal interactions between gut and brain. Discov Med 2010; 10: 543-552.
71. De Graaf C, Blom WAM, Smeets PAM, Stafleu A, Hendriks HFJ. Biomarkers of satiation and satiety. Am J Clin Nutr 2004; 79: 946.
72. Crespo CS, Cachero AP, Jiménez LP, Barrios V, Ferreiro EA. Peptides and food intake. Front Endocrinol 2014; 5: 58.
73. Chearskul S, Delbridge E, Shulkes A, Proietto J, Kriketos A. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr 2008; 87: 1238-1246.
74. Martins C, Kulseng B, Rehfeld JF, King NA, Blundell JE. Effect of chronic exercise on appetite control in overweight and obese individuals. Med Sci Sports Exerc 2013; 45: 805-812.
75. Bailey DM, Davies B, Castell LM, Newsholme EA, Calam J. Physical exercise and normobaric hypoxia: independent modulators of peripheral cholecystokinin metabolism in man. J Appl Physiol (1985) 2001; 90: 105-113.
76. Sliwowski Z, Lorens K, Konturek SJ, Bielanski W, Zoladz JA. Leptin, gastrointestinal and stress hormones in response to exercise in fasted or fed subjects and before or after blood donation. J Physiol Pharmacol 2001; 52: 53-70.
77. Schubert MM, Desbrow B, Sabapathy S, Leveritt M. Acute exercise and subsequent energy intake. A meta-Analysis. Appetite 2013; 63: 92-104.
78. Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1247-E1259.
79. Donato Jr J, Cravo RM, Frazao R, Elias CF. Hypothalamic sites of leptin action linking metabolism and reproduction. Neuroendocrinology 2011; 93: 9-18.
80. Akieda-Asai S, Poleni PE, Date Y. Coinjection of CCK and leptin reduces food intake via increased CART/TRH and reduced AMPK phosphorylation in the hypothalamus. Am J Physiol Endocrinol Metab 2014; 306: E1284-E1291.
81. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84: 3686-3695.
82. Paz-Filho G, Mastronardi C, Delibasi T, Wong ML, Licinio J. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arq Bras Endocrinol Metabol 2010; 54: 690-697.
83. Herpertz S, Albers N, Wagner R, Pelz B, Kopp W, Mann K, et al. Longitudinal changes of circadian leptin, insulin and cortisol plasma levels and their correlation during refeeding in patients with anorexia nervosa. Eur J Endocrinol 2000; 142: 373-379.
84. Carlson JJ, Turpin AA, Wiebke G, Hunt SC, Adams TD. Pre- and post- prandial appetite hormone levels in normal weight and severely obese women. Nutr Metab 2009; 6: 32.
85. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630.
86. Kissileff HR, Thornton JC, Torres MI, Pavlovich K, Mayer LS, Kalari V, et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am J Clin Nutr 2012; 95: 309-317.
87. Tsofliou F, Pitsiladis YP, Malkova D, Wallace AM, Lean ME. Moderate physical activity permits acute coupling between serum leptin and appetite-satiety measures in obese women. Int J Obes Relat Metab Disord 2003; 27: 1332-1339.
88. Vatansever-Ozen S, Tiryaki-Sonmez G, Bugdayci G, Ozen G. The effects of exercise on food intake and hunger: relationship with acylated ghrelin and leptin. J Sports Sci Med 2011; 10: 283-291.
89. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
90. Neary NM, Druce MR, Small CJ, Bloom SR. Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut 2006; 55: 135.
91. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004; 287: E297-E304.
92. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
93. Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A, et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006; 55: 327-333.
94. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
95. Lippl F, Erdmann J, Steiger A, Lichter N, Czogalla-Peter C, Bidlingmaier M, et al. Low-Dose ghrelin infusion-Evidence against a hormonal role in food intake. Regul Pept 2012; 174: 26-31.
96. Deighton K, Batterham RL, Stensel DJ. Appetite and gut peptide responses to exercise and calorie restriction. The effect of modest energy deficits. Appetite 2014; 81: 52-59.
97. Delhanty PJ, Neggers SJ, van der Lely AJ. Should we consider des-Acyl ghrelin as a separate hormone and if so, what does it do? Front Horm Res 2014; 42: 163-174.
98. Callaghan B, Furness JB. Novel and conventional receptors for ghrelin, desacylghrelin, and pharmacologically related compounds. Pharmacol Rev 2014; 66: 984-1001.
99. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87: 2984.
100. Karlsson J, Persson LO, Sjostrom L, Sullivan M. Psychometric properties and factor structure of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study. Int J Obes Relat Metab Disord 2000; 24: 1715-1725.
101. Zunker C, Karr T, Saunders R, Mitchell JE. Eating behaviors post-bariatric surgery: a qualitative study of grazing. Obes Surg 2012; 22: 1225-1231.
102. Ata SM, Vaishnav U, Puglisi M, Lofgren IE, Wood RJ, Volek JS, et al. Macronutrient composition and increased physical activity modulate plasma adipokines and appetite hormones during a weight loss intervention. J Womens Health 2010; 19: 139-145.
103. Hooper LE, Foster-Schubert KE, Weigle DS, Sorensen B, Ulrich CM, McTiernan A. Frequent intentional weight loss is associated with higher ghrelin and lower glucose and androgen levels in postmenopausal women. Nutr Res 2010; 30: 163-170.
104. Martins C, Morgan LM, Bloom SR, Robertson MD. Effects of exercise on gut peptides, energy intake and appetite. J Endocrinol 2007; 193: 251-258.
105. Foster-Schubert KE, McTiernan A, Frayo RS, Schwartz RS, Rajan KB, Yasui Y, et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab 2005; 90: 820-825.
106. King NA, Caudwell PP, Hopkins M, Stubbs JR, Naslund E, Blundell JE. Dual-process action of exercise on appetite control: increase in orexigenic drive but improvement in meal-induced satiety. Am J Clin Nutr 2009; 90: 921-927.
107. Morpurgo PS, Resnik M, Agosti F, Cappiello V, Sartorio A, Spada A. Ghrelin secretion in severely obese subjects before and after a 3-week integrated body mass reduction program. J Endocrinol Invest 2003; 26: 723-727.
108. Kim HJ, Lee S, Kim TW, Kim HH, Jeon TY, Yoon YS, et al. Effects of exerciseinduced weight loss on acylated and unacylated ghrelin in overweight children. Clin Endocrinol (Oxf) 2008; 68: 416-422.
109. Konturek SJ, Pepera J, Zabielski K, Konturek PC, Pawlik T, Szlachcic A, et al. Braingut axis in pancreatic secretion and appetite control. J Physiol Pharmacol 2003; 54: 293-317.
110. Mason C, Xiao L, Imayama I, Duggan CR, Campbell KL, Kong A, et al. The effects of separate and combined dietary weight loss and exercise on fasting ghrelin concentrations in overweight and obese women: a randomized controlled trial. Clin Endocrinol (Oxf) 2015; 82: 369-376.
111. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, et al. The hypothalamic-pituitary-Adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993; 77: 341-346.
112. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007; 100: 395-404.
113. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996; 271: E317-E325.
114. Vicennati V, Pasqui F, Cavazza C, Pagotto U, Pasquali R. Stress-related development of obesity and cortisol in women. Obesity 2009; 17: 1678-1683.
115. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853-1859.
116. Chandarana K, Drew ME, Emmanuel J, Karra E, Gelegen C, Chan P, et al. Subject standardization, acclimatization, and sample processing affect gut hormone levels and appetite in humans. Gastroenterology 2009; 136: 2115-2126.
117. Espelund U, Hansen TK, Hojlund K, Beck-Nielsen H, Clausen JT, Hansen BS, et al. Fasting unmasks a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J Clin Endocrinol Metab 2005; 90: 741-746.
118. Otto B, Tschop M, Heldwein W, Pfeiffer AF, Diederich S. Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans. Eur J Endocrinol 2004; 151: 113-117.
119. Hallschmid M, Benedict C, Born J, Fehm HL, Kern W. Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 2004; 83: 55-64.
120. Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg 2007; 17: 732-736.
121. Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother 2010; 44: 538-545.
122. Culnan DM, Cooney RN, Stanley B, Lynch CJ. Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass. Obesity 2009; 17: 46-52.
123. Sjodin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes 2010; 34: 1634-1643.
124. den Hoed M, Smeets AJ, Veldhorst MA, Nieuwenhuizen AG, Bouwman FG, Heidema AG, et al. SNP analyses of postprandial responses in (an)orexigenic hormones and feelings of hunger reveal long-Term physiological adaptations to facilitate homeostasis. Int J Obes 2008; 32: 1790-1798.
125. Kovacs EM, Lejeune MP, Westerterp-Plantenga MS. The effects of enterostatin intake on food intake and energy expenditure. Br J Nutr 2003; 90: 207-214.
126. Reitman ML, Dishy V, Moreau A, Denney WS, Liu C, Kraft WK, et al. Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients. J Clin Pharmacol 2012; 52: 1306-1316.
127. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; CD006423.
128. Dolan LC, Potter SM, Burdock GA. Evidence-based review on the effect of normal dietary consumption of fructose on blood lipids and body weight of overweight and obese individuals. Crit Rev Food Sci Nutr 2010; 50: 889-918.
129. Dolan LC, Potter SM, Burdock GA. Evidence-based review on the effect of normal dietary consumption of fructose on development of hyperlipidemia and obesity in healthy, normal weight individuals. Crit Rev Food Sci Nutr 2010; 50: 53-84.
130. Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energyrestricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-Analysis of randomized controlled trials. Am J Clin Nutr 2012; 96: 1281-1298.
131. Williams G, Cardoso HM, Lee YC, Ball JM, Ghatei MA, Stock MJ, et al. Hypothalamic regulatory peptides in obese and lean Zucker rats. Clin Sci 1991; 80: 419-426.
132. Dirksen C, Jorgensen NB, Bojsen-Moller KN, Kielgast U, Jacobsen SH, Clausen TR, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-En-Y gastric bypass. Int J Obes 2013; 37: 1452-1459.
133. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 1635-1639.
134. Hoybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm IGF Res 2004; 14: 1-15.
135. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 2007; 293: E604-E609.
136. Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin 2013; 29: 839-848.
137. Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Borowiec M. Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes Metab 2000; 2: 99-103.
138. Ehrlich S, Leopold K, Merle JV, Theophil I, Haag W, Lautenschlager M, et al. Trajectories of agouti-related protein and leptin levels during antipsychoticassociated weight gain in patients with schizophrenia. J Clin Psychopharmacol 2012; 32: 767-772.
139. Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, et al. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res 2012; 1431: 46-52.
140. Turenius CI, Htut MM, Prodon DA, Ebersole PL, Ngo PT, Lara RN, et al. GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res 2009; 1262: 16-24.
141. Elias E, Benrick A, Behre CJ, Ekman R, Zetterberg H, Stenlof K, et al. Central nervous system lipocalin-Type prostaglandin D2-synthase is correlated with orexigenic neuropeptides, visceral adiposity and markers of the hypothalamicpituitary-Adrenal axis in obese humans. J Neuroendocrinol 2011; 23: 501-507.
142. Bowen J, Noakes M, Trenerry C, Clifton PM. Energy intake, ghrelin, and cholecystokinin after different carbohydrate and protein preloads in overweight men. J Clin Endocrinol Metab 2006; 91: 1477-1483.
143. Hermanussen M, Garcia AP, Sunder M, Voigt M, Salazar V, Tresguerres JA. Obesity, voracity, and short stature: the impact of glutamate on the regulation of appetite. Eur J Clin Nutr 2006; 60: 25-31.
144. Carnier J, de Mello MT, Ackel DC, Corgosinho FC, Campos RM, Sanches Pde L, et al. Aerobic training (AT) is more effective than aerobic plus resistance training (AT+RT) to improve anorexigenic/orexigenic factors in obese adolescents. Appetite 2013; 69: 168-173.
145. Oruc AS, Mert I, Akturk M, Aslan E, Polat B, Buyukkagnici U, et al. Ghrelin and motilin levels in hyperemesis gravidarum. Arch Gynecol Obstet 2013; 287: 1087-1092.
146. Kentish SJ, Wittert GA, Blackshaw LA, Page AJ. A chronic high fat diet alters the homologous and heterologous control of appetite regulating peptide receptor expression. Peptides 2013; 46: 150-158.
147. Cigdem Arica P, Kocael A, Tabak O, Taskin M, Zengin K, Uzun H. Plasma ghrelin, leptin, and orexin-A levels and insulin resistance after laparoscopic gastric band applications in morbidly obese patients. Minerva Med 2013; 104: 309-316.
148. Carrero JJ, Witasp A, Stenvinkel P, Qureshi AR, Heimburger O, Barany P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010; 25: 901-906.